Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants.
about
Innate immune function of the neisserial porins and the relationship to vaccine adjuvant activityThe TLR2 Binding Neisserial Porin PorB Enhances Antigen Presenting Cell Trafficking and Cross-presentation.Delivery of foreign antigens by engineered outer membrane vesicle vaccines.Neisseria meningitidis lipopolysaccharide modulates the specific humoral immune response to neisserial porins but has no effect on porin-induced upregulation of costimulatory ligand B7-2.Peptide mimicry of the meningococcal group C capsular polysaccharideIntranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice.Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines.Measles vaccination: new strategies and formulations.Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge.Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations.Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection.Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.Engineered human vaccines.Engineering the cell surface display of cohesins for assembly of cellulosome-inspired enzyme complexes on Lactococcus lactis.Liposome technology for industrial purposes.
P2860
Q30156878-84275538-0CE7-4D26-A928-03AAF0BED4D6Q33673210-BC86D309-C39B-4245-A360-BD7AE3E8EE08Q33733590-5466B332-3FA9-4E43-8A4C-CBE2E2DA7575Q34008652-ED4BE873-D7D9-4570-AC78-4C78BD9F3A0EQ34404304-BE76628D-8E56-4FF2-9BA3-EB0E4A3E3916Q35490149-6F9FD67B-C827-438F-86DE-EE2AFE5C7E5AQ35529377-C7992EF2-3601-4DE8-A09F-31BBA926169EQ37290110-1154C841-73D7-44C3-9C58-243AD6512BD3Q37347397-57AAAB8F-E267-4356-B32A-0B33A5100517Q37812128-9FC8A34B-2654-49CB-B3CE-CDB300ACE298Q37857257-781F606A-0BD6-463F-9D6D-D163DD196089Q39822312-142402C1-CE3C-4166-9929-79FA1237886EQ40433276-B7EFD2E1-A050-4F55-88B4-34AC53C3A460Q40754536-D81739E5-8D23-45F4-A74A-395A82E304DEQ42414145-7CE20287-A53E-4D0B-81BB-EA28E392AE68Q42705145-7C74F077-DD39-45BD-9F16-85EB89B27D48
P2860
Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Peptides bound to proteosomes ...... immunogenic without adjuvants.
@en
Peptides bound to proteosomes ...... immunogenic without adjuvants.
@nl
type
label
Peptides bound to proteosomes ...... immunogenic without adjuvants.
@en
Peptides bound to proteosomes ...... immunogenic without adjuvants.
@nl
prefLabel
Peptides bound to proteosomes ...... immunogenic without adjuvants.
@en
Peptides bound to proteosomes ...... immunogenic without adjuvants.
@nl
P2093
P2860
P356
P1476
Peptides bound to proteosomes ...... immunogenic without adjuvants.
@en
P2093
P2860
P304
P356
10.1084/JEM.167.2.658
P407
P577
1988-02-01T00:00:00Z